

4.3.1 Appendix 1: Policies published (7) between (1 April 2026 –31 May 2026)

Policy Number	Title	Commissioning Team	Publication date
PPS152	Drug treatment for paroxysmal nocturnal haemoglobinuria. Policy Position Statement [UPDATE]	Meds Optimisation Team for Cancer and Blood	05 May 2026
PPS327	Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over, Policy Position Statement [NEW]	Meds Optimisation Team for Cancer and Blood	23 April 2026
CP172	Specialised Paediatric Rheumatology Service, Commissioning Policy [UPDATE]	Women and Children	23 April 2026
PPS198	Cystic Fibrosis Modulator Therapies, Policy Position Statement [UPDATE]	Meds Optimisation Team for Cardiac	23 April 2026
PPS304	Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B (adults). Policy Position Statement [NEW]	Meds Optimisation Team for Cancer and Blood	23 April 2026
PPS321	Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over, Policy Position Statement [NEW]	Meds Optimisation Team for Women and Children	23 April 2026
PPS292	Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over [UPDATE]	Meds Optimisation Team for Cancer and Blood	20/04/2026